High Purity CAS 941678-49-5 Ruxolitinib Intermediate Ruxolitinib

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: QS-Ruxolitinib
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Product Name: Ruxolitinib
• Name: Ruxolitinib Powder
• Appearance: White Powder
• Colour: White
• Grade: Pharmaceutical Grade
• Assay: >99%
• Application: API
• Specific: COA
• Test Method: HPLC
• Mf: C17h18n6
• MW: 306.36
• CAS: 941678-49-5
• Density: 1.40
• Boiling Point: 760 Mmhg
• Refractive Index: 1.747
• Transport Package: Negotiable
• Specification: >99%
• Trademark: QS-Ruxolitinib
• Origin: Xian
• Production Capacity: 500kg/Month

Product Description

High Purity CAS 941678-49-5 Ruxolitinib Intermediate Ruxolitinib

Product Description

Product Details

Product Name	Ruxolitinib
Appearance	White Powder
Assay	99%
MW	306.36
MF	C17H18N6

Ruxolitinib is the first oral medication approved by the US Food and Drug Administration (FDA) for the treatment of bone marrow fibrosis.
Ruxolitinib is a tyrosine kinase inhibitor, a small molecule inhibitor of protein kinases JAK1 and JAK2, suitable for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post polycythemia vera myelofibrosis, and post thrombocytopenia myelofibrosis.

Application&Function

Antitumor activity
Ruxolitinib can induce autophagy and kill tumor cells through toxic mitochondrial autophagy. Autophagy is a self degradation and self-protection mechanism within cells, while mitochondrial autophagy selectively clears damaged or dysfunctional mitochondria. In this way, Ruxolitinib can inhibit the survival and proliferation of tumor cells, achieving anti-tumor effects.
Treatment of bone marrow fibrosis
Rusolitinib is the first oral medication approved by the US Food and Drug Administration (FDA) for the treatment of bone marrow fibrosis. As a small molecule inhibitor of protein kinases JAK1 and JAK2, it is suitable for treating intermediate or high-risk myelofibrosis, including primary myelofibrosis, post polycythemia vera myelofibrosis, and post thrombocytopenia myelofibrosis. By inhibiting the activity of JAK1 and JAK2 kinases, rossolitinib can regulate the bone marrow microenvironment, reduce abnormal cell proliferation and inflammatory response, thereby improving the symptoms and prognosis of patients with myelofibrosis.
 

Specification